Matching-adjusted indirect comparison of phase 3 clinical trial outcomes of OC-01 (varenicline solution) nasal spray and lifitegrast 5% ophthalmic solution for the treatment of dry...

por White, Darrell E, Hendrix, Laura H, Sun, Lucille, Tam, Iris, Macsai, Marian, Gibson, Andrea A
Publicado 2023

Safety, adherence and discontinuation in varenicline solution nasal spray clinical trials for dry eye disease

por Hauswirth, Scott G, Kabat, Alan G, Hemphill, Mandy, Somaiya, Karan, Hendrix, Laura H, Gibson, Andrea A
Publicado 2023

Does Menopausal Status Affect Dry Eye Disease Treatment Outcomes with OC-01 (Varenicline Solution) Nasal Spray? A Post Hoc Analysis of ONSET-1 and ONSET-2 Clinical Trials

por Nijm, Lisa M., Zhu, Dagny, Hemphill, Mandy, Blemker, Gretchen L., Hendrix, Laura H., Kabat, Alan G., Gibson, Andrea A.
Publicado 2022

OC-01 (Varenicline Solution) Nasal Spray for the Treatment of Dry Eye Disease Signs and Symptoms in Subjects with Autoimmune Disease: Integrated Data from ONSET-1 and ONSET-2

por Schallhorn, Julie M, McGee, Selina, Nau, Jeffrey, Macsai, Marian, Gibson, Andrea, Blemker, Gretchen, Hendrix, Laura H, Massaro-Giordano, Mina
Publicado 2023

Does Dry Eye Disease Severity Impact Efficacy of Varenicline Solution Nasal Spray on Sign and Symptom Treatment Outcomes?

por Sheppard, John D., O'Dell, Leslie E., Karpecki, Paul M., Raizman, Michael B., Whitley, Walter O., Blemker, Gretchen, Hemphill, Mandy, Hendrix, Laura H., Gibson, Andrea, Macsai, Marian
Publicado 2023